All news

A director proposes selling 1,203 shares of Quest Diagnostics (NYSE: DGX).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Quest Diagnostics director Gary M. Pfeiffer has proposed selling 1,203 common shares, valued at $292,329, on approximately October 26, 2026. These shares originated from restricted stock vesting on May 15, 2026, received as compensation. The transaction will be handled by Fidelity Brokerage Services LLC on the NYSE.

Read original source

DGX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.